EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

Apostolia Maria Tsimberidou iD, Henry Hiep Vo, Jennifer Beck, Chi-Sheng Shia, Pei Hsu, Tillman E Pearce

JCO Precision Oncology · 2023

DOI: 10.1200/po.22.00496 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Apostolia Maria Tsimberidou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Immunoconjugates, Antineoplastic Agents, Adenocarcinoma, Neutropenia. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE OBI-999 is a novel antibody-drug conjugate comprising the Globo H–targeting antibody (OBI-888) linked to the cytotoxic payload monomethyl auristatin E. OBI-999 demonstrated excellent dose-dependent tumor growth inhibition in breast, gastric, and pancreatic cancer xenograft models as well as a lung cancer patient–derived xenograft model. We conducted a phase I study of OBI-999 monotherapy in patients with advanced cancer (ClinicalTrials.gov identifier: NCT04084366 ). PATIENTS AND METHODS OBI-999 was administered intravenously at doses of 0.4, 0.8, 1.2, and 1.6 mg/kg every 21 days as part of a 3 + 3 trial design. Primary end points were the incidence of dose-limiting toxicities and adverse events and determination of the maximum tolerated dose (MTD)/recommended phase II dose. RESULTS Fifteen adult patients were treated. OBI-999 was well tolerated up to 1.2 mg/kg, the maximum tolerated dose. The most common treatment-emergent adverse events were neutropenia and anemia. OBI-999 exhibited nonlinear pharmacokinetics at all doses, with lower clearance at higher doses. The three patients treated at the 1.6 mg/kg dose level developed grade 4 neutropenia during cycles 1 and 2. Five (33.3%) patients had stable disease (SD) including one patient with adenoid cystic carcinoma of the oropharynx with SD for 13 cycles and one patient with gastroesophageal junction adenocarcinoma with SD for eight cycles. OBI-999 was well tolerated; however, dose-dependent, noncumulative neutropenia was dose-limiting. CONCLUSION The recommended phase II dose was determined to be 1.2 mg/kg once every 3 weeks. A phase II cohort-expansion study is now enrolling patients with pancreatic, colorectal, and other cancers expressing high levels of Globo H.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesAntineoplastic AgentsAdenocarcinomaNeutropeniaAdultHumansAntibodies, Monoclonal

Substanzen

ImmunoconjugatesAntineoplastic AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • OBI Pharma Inc, Taipei City, Taiwan.
  • OBI Pharma USA, Inc, San Diego, CA.

ORCID-Profile: Apostolia Maria Tsimberidou

Zitieren

APA

Tsimberidou, A. M., Vo, H. H., Beck, J., Shia, C. S., Hsu, P., & Pearce, T. E. (2023). First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors. JCO Precision Oncology. https://doi.org/10.1200/po.22.00496

Vancouver

Tsimberidou AM, Vo HH, Beck J, Shia CS, Hsu P, Pearce TE. First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors. JCO Precision Oncology. 2023. doi:10.1200/po.22.00496

BibTeX
@article{Tsimberidou2023,
  author = {Tsimberidou, Apostolia Maria and Vo, Henry Hiep and Beck, Jennifer and Shia, Chi-Sheng and Hsu, Pei and Pearce, Tillman E},
  title = {First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors},
  journal = {JCO Precision Oncology},
  year = {2023},
  doi = {10.1200/po.22.00496}
}
Kostenlos starten →